Good morning :)
Place Order
Add to Watchlist

Alembic Pharmaceuticals Ltd

APLLTD Share Price

977.100.86% (-8.50)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹19,206 cr, stock is ranked 362

Stock is 3.08x as volatile as Nifty

APLLTD Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹19,206 cr, stock is ranked 362

Stock is 3.08x as volatile as Nifty

APLLTD Performance & Key Metrics

APLLTD Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
32.923.701.13%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.596.400.79%

APLLTD Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
64%
Analysts have suggested that investors can buy this stock

from 11 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

APLLTD Company Profile

Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).

Investor Presentation

View older View older 

May 6, 2025

PDF
View Older Presentations

APLLTD Similar Stocks (Peers)

Compare with peers Compare with peers 

APLLTD Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.50
36.50
1Y Return
4.00%
4.00%
Buy Reco %
87.10
87.10
PE Ratio
22.64
22.64
1Y Return
2.34%
2.34%
Buy Reco %
73.33
73.33
PE Ratio
59.13
59.13
1Y Return
13.13%
13.13%
Buy Reco %
70.83
70.83
PE Ratio
18.58
18.58
1Y Return
4.24%
4.24%
Buy Reco %
51.72
51.72
PE Ratio
52.73
52.73
1Y Return
18.31%
18.31%
Buy Reco %
81.25
81.25
Compare with Peers

APLLTD Sentiment Analysis

APLLTD Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

APLLTD Stock Summary · May 2025

Alembic Pharmaceuticals demonstrated robust revenue growth of 17% in Q4 FY'25, driven by strong performance in key segments like gynecology and animal health, despite facing challenges in profitability due to increased tax provisions and declining gross margins. The company is strategically managing inventory levels in anticipation of multiple product launches, while also investing significantly in R&D and new manufacturing facilities to support future growth, particularly in complex products. Internationally, the business thrived, especially in the ex-US market, although pricing pressures in the U.S. segment raised concerns. Looking ahead, management remains optimistic about mid to high teens growth in FY'26, contingent on successful product introductions and market strategies.

APLLTD Stock Growth Drivers
APLLTD Stock Growth Drivers
7
  • Strong Financial Performance

    Alembic Pharmaceuticals reported a revenue growth of 17% for Q4 FY'25, reaching Rs. 1,770 crores,

  • Growth in Key Business Segments

    The India business achieved an 8% growth in Q4, with a topline of Rs. 545

APLLTD Stock Challenges
APLLTD Stock Challenges
5
  • Declining Earnings and Profitability

    Alembic Pharmaceuticals has reported a decrease in earnings per share (EPS) for the current quarter

  • Increased Borrowings and Working Capital Concerns

    The company has seen a rise in short-term borrowings due to increased working capital requirements.

APLLTD Forecast

APLLTD Forecasts

Price

Revenue

Earnings

APLLTD

APLLTD

Income

Balance Sheet

Cash Flow

APLLTD Income Statement

APLLTD Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.85%, vs industry avg of 10.1%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.84% to 1.62%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -6.78%, vs industry avg of 20.04%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue3,107.173,137.843,944.064,610.695,480.425,361.535,655.366,256.946,728.376,729.03
Raw Materialssubtract928.05927.621,084.971,249.981,451.271,489.611,630.171,857.922,083.135,664.50
Power & Fuel Costsubtract64.2070.3588.86102.40118.72120.84151.54173.37179.69
Employee Costsubtract558.83622.81746.69906.441,051.171,133.001,169.131,446.291,562.34
Selling & Administrative Expensessubtract791.13700.51961.11913.651,104.031,354.871,474.001,543.701,650.86
Operating & Other expensessubtract147.67166.42179.47253.92187.65333.31550.33274.97187.82
Depreciation/Amortizationsubtract82.97105.46115.23157.32183.48286.78275.43272.67278.58278.58
Interest & Other Itemssubtract5.233.4018.4127.1616.0217.7350.1756.1978.7778.77
Taxes & Other Itemssubtract125.93128.64164.95171.00221.58104.4512.6016.01123.76123.75
EPS21.3921.8931.0043.9759.5526.5017.4031.3329.6829.68
DPS4.004.005.5010.0014.0010.008.0011.0011.0011.00
Payout ratio0.190.180.180.230.240.380.460.350.370.37

APLLTD Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 6PDF
Feb 3PDF
Nov 7PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 4PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 5PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF

Investor Presentation

Jul 29PDF
FY 2016FY 2016

Annual report

PDF

Investor Presentation

Jan 21PDF
 

APLLTD Stock Peers

APLLTD Past Performance & Peer Comparison

APLLTD Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Alembic Pharmaceuticals Ltd32.923.701.13%
Sun Pharmaceutical Industries Ltd36.505.500.96%
Cipla Ltd22.643.821.08%
Torrent Pharmaceuticals Ltd59.1314.890.18%

APLLTD Stock Price Comparison

Compare APLLTD with any stock or ETF
Compare APLLTD with any stock or ETF
APLLTD
Loading...

APLLTD Holdings

APLLTD Shareholdings

APLLTD Promoter Holdings Trend

APLLTD Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

APLLTD Institutional Holdings Trend

APLLTD Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

APLLTD Shareholding Pattern

APLLTD Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding69.67%9.20%7.23%3.94%9.96%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

APLLTD Shareholding History

APLLTD Shareholding History

Dec '23MarJunSepDec '24Mar4.52%4.46%4.32%3.94%4.17%3.94%

Mutual Funds Invested in APLLTD

Mutual Funds Invested in APLLTD

No mutual funds holding trends are available

Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.8742%2.01%0.24%49/82 (+2)
1.6264%1.61%0.22%29/60 (+9)
0.8279%0.94%0.15%60/83 (-5)

Compare 3-month MF holding change on Screener

APLLTD Insider Trades & Bulk Stock Deals

APLLTD Insider Trades & Bulk Stock Deals

Loading...

smallcases containing APLLTD stock

smallcases containing APLLTD stock

Looks like this stock is not in any smallcase yet.

APLLTD Events

APLLTD Events

APLLTD Dividend Trend

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.13%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.26 every year

Dividends

Corp. Actions

Announcements

Legal Orders

APLLTD Dividend Trend

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.13%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.26 every year

APLLTD Upcoming Dividends

APLLTD Upcoming Dividends

Cash Dividend

Ex DateEx DateJul 29, 2025

Final
Final | Div/Share: ₹11.00

Dividend/Share

11.00

Ex DateEx Date

Jul 29, 2025

APLLTD Past Dividends

APLLTD Past Dividends

Cash Dividend

Ex DateEx DateJul 15, 2024

Final
Final | Div/Share: ₹11.00

Dividend/Share

11.00

Ex DateEx Date

Jul 15, 2024

Cash Dividend

Ex DateEx DateJul 28, 2023

Final
Final | Div/Share: ₹8.00

Dividend/Share

8.00

Ex DateEx Date

Jul 28, 2023

Cash Dividend

Ex DateEx DateAug 17, 2022

Interim
Interim | Div/Share: ₹10.00

Dividend/Share

10.00

Ex DateEx Date

Aug 17, 2022

Cash Dividend

Ex DateEx DateJul 19, 2021

Final
Final | Div/Share: ₹14.00

Dividend/Share

14.00

Ex DateEx Date

Jul 19, 2021

Cash Dividend

Ex DateEx DateMar 16, 2020

Interim
Interim | Div/Share: ₹7.00

Dividend/Share

7.00

Ex DateEx Date

Mar 16, 2020

APLLTD Stock News & Opinions

APLLTD Stock News & Opinions

Spotlight
Alembic Pharma appoints G. Krishnan as new CFO

Krishnan is a seasoned finance professional with over 22 years of experience across the pharmaceuticals, life sciences, telecom, and social sectors. He is a qualified Chartered Accountant (CA), Company Secretary (CS), and Cost and Management Accountant (CMA). Prior to joining Alembic, Krishnan served as Vice President and CFO at Syngene Scientific Solutions, a subsidiary of Syngene International, since May 2020. During his tenure, he played a crucial role in driving strategy, business finance, mergers & acquisitions, governance and risk management. He has also held key leadership positions at Vodafone and Tata Trusts. Krishnan brings with him expertise in business finance, M&A, scalable systems implementation, and governance frameworks, along with managing diverse finance teams. Meanwhile, the company also informed that R. K. Baheti, Director ' Finance and the current CFO, has relinquished his role as CFO effective 7 July 2025. However, he will continue to serve on the board as an executive director, in line with the terms of his appointment. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.37% to Rs 1,004.20 on the BSE. Powered by Capital Market - Live

3 days agoCapital Market - Live
Spotlight
Alembic Pharma inks deal to acquire Utility Therapeutics for $12 million

Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). The first product 'Pivya' is an FDA approved product to treat uncomplicated UTIs in the US market. The second product 'MEC' is in development for the treatment of complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years. Alembic Pharma stated that the acquisition has been made to market the US FDA approved product and under-development product owned by the Utility in USA. The acquisition cost involves a cash component plus profit share out of future profits. The total amount payable is approximately $12 million. The payout would happen in staggered manner over period of time, depending on milestones achieved. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. The scrip advanced 0.95% to currently trade at Rs 999.05 on the BSE. Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Alembic Pharmaceuticals announces acquisition of Utility Therapeutics

Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acquired Utility Therapeutics for a consideration of $12 million in staggered manner over period of time, depending on milestones achieved. Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). -'Pivya' is an FDA approved product to treat uncomplicated UTIs in the US market. -'MEC' is a product in development for treatment of the complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Volumes soar at Alembic Pharmaceuticals Ltd counter

Jyoti CNC Automation Ltd, Raymond Ltd, TBO Tek Ltd, Raymond Lifestyle Ltd are among the other stocks to see a surge in volumes on NSE today, 30 June 2025.Alembic Pharmaceuticals Ltd recorded volume of 128.6 lakh shares by 14:14 IST on NSE, a 124.17 times surge over two-week average daily volume of 1.04 lakh shares. The stock gained 9.79% to Rs.1,063.80. Volumes stood at 1.17 lakh shares in the last session.Jyoti CNC Automation Ltd registered volume of 177.53 lakh shares by 14:14 IST on NSE, a 74.1 fold spurt over two-week average daily volume of 2.40 lakh shares. The stock slipped 5.83% to Rs.1,060.00. Volumes stood at 1.17 lakh shares in the last session.Raymond Ltd clocked volume of 91.06 lakh shares by 14:14 IST on NSE, a 21.3 times surge over two-week average daily volume of 4.28 lakh shares. The stock gained 14.44% to Rs.714.50. Volumes stood at 12.85 lakh shares in the last session.TBO Tek Ltd recorded volume of 10.93 lakh shares by 14:14 IST on NSE, a 12.52 times surge over two-week average daily volume of 87327 shares. The stock gained 0.56% to Rs.1,399.90. Volumes stood at 2.02 lakh shares in the last session.Raymond Lifestyle Ltd saw volume of 38.22 lakh shares by 14:14 IST on NSE, a 9.57 fold spurt over two-week average daily volume of 3.99 lakh shares. The stock increased 12.71% to Rs.1,377.60. Volumes stood at 12.04 lakh shares in the last session.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Alembic Pharmaceuticals Ltd leads gainers in 'A' group

Jindal Worldwide Ltd, RattanIndia Power Ltd, AAVAS Financiers Ltd and Force Motors Ltd are among the other gainers in the BSE's 'A' group today, 30 June 2025.Alembic Pharmaceuticals Ltd surged 13.49% to Rs 1103 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 4.68 lakh shares were traded on the counter so far as against the average daily volumes of 5051 shares in the past one month. Jindal Worldwide Ltd soared 10.36% to Rs 61.58. The stock was the second biggest gainer in 'A' group. On the BSE, 4.29 lakh shares were traded on the counter so far as against the average daily volumes of 31183 shares in the past one month. RattanIndia Power Ltd spiked 6.94% to Rs 15.4. The stock was the third biggest gainer in 'A' group. On the BSE, 374.19 lakh shares were traded on the counter so far as against the average daily volumes of 193.98 lakh shares in the past one month. AAVAS Financiers Ltd spurt 6.20% to Rs 2115.45. The stock was the fourth biggest gainer in 'A' group. On the BSE, 33883 shares were traded on the counter so far as against the average daily volumes of 7113 shares in the past one month. Force Motors Ltd advanced 6.06% to Rs 15377.15. The stock was the fifth biggest gainer in 'A' group. On the BSE, 8028 shares were traded on the counter so far as against the average daily volumes of 12061 shares in the past one month. Powered by Capital Market - Live

1 week agoCapital Market - Live
Live Market Update
Nifty slides below 25,600; private bank shares under pressure

The domestic equity benchmarks traded with modest losses in morning trade, weighed down by a mix of global and domestic factors. India's recent forex data revealed a decline in its reserves. Meanwhile, the Israel-Iran truce helped ease geopolitical tensions, and growing optimism over a potential US-India trade deal supported sentiment. Inflows from foreign institutional investors further contributed to the positive undertone. Even concerns around the July 9 U.S. tariff deadline took a backseat, as reports of a likely extension helped calm investor nerves. The Nifty traded below the 25,600 level. Private bank shares witnessed profit booking after advancing in the past two consecutive trading sessions. At 10:28 IST, the barometer index, the S&P BSE Sensex, declined 284.60 points or 0.33% to 83,778.85. The Nifty 50 index lost 82.05 points or 0.32% to 25,556.75. In the broader market, the S&P BSE Mid-Cap index rose 0.25% and the S&P BSE Small-Cap index jumped 0.62%. The market breadth was strong. On the BSE, 2,321 shares rose and 1,324 shares fell. A total of 222 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, rallied 3.39% to 12.81. Economy: India's forex reserves dropped by USD 1.01 billion to USD 697.93 billion for the week ended June 20, the Reserve Bank of India said on Friday. For the week ended June 20, foreign currency assets, a major component of the reserves, dropped by USD 357 million to USD 589.06 billion, the data released on Friday showed. The gold reserves were down by USD 573 million to USD 85.74 billion during the week, the RBI said. The Special Drawing Rights (SDRs) declined by USD 85 million to USD 18.672 billion, the apex bank said. India's reserve position with the IMF also declined by USD 1 million to USD 4.45 billion in the reporting week, the apex bank data showed. Buzzing Index: The Nifty Private Bank index fell 0.31% to 28,417.85. The index rallied 1.34% in the past two consecutive trading sessions. Kotak Mahindra Bank (down 1.41%), HDFC Bank (down 0.60%), Axis Bank (down 0.52%) and ICICI Bank (down 0.50%) were the top losers. On the other hand, RBL Bank (up 3.73%), Bandhan Bank (up 2.35%) and Federal Bank (up 1.88%) edged higher. Stocks in Spotlight: Alembic Pharmaceuticals surged 8.40% after the company received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection. ITD Cementation India rallied 4.22% after the company secured an international marine contract worth $67.4 million (approximately Rs 580 crore) for jetty construction works related to the Ruwais LNG project in Abu Dhabi. Interarch Building Solutions rose 0.69%. The company announced that it has secured an order worth Rs 77 crore from Amara Raja Infra. Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Alembic Pharma jumps after receiving USFDA nod for Doxorubicin Hydrochloride Injection

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, of Baxter Healthcare Corporation. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. According to IQVIA, the estimated market size for Doxorubicin Hydrochloride Liposome Injection single-dose vials is $29 million for the 12 months ending March 2025. Alembic now has a cumulative total of 224 ANDA approvals from the USFDA, including 201 final approvals and 23 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Alembic Pharmaceuticals announces change in senior management

Alembic Pharmaceuticals announced that Viraj Save, Executive Vice President - Sales and Marketing has resigned from the said position and relieved w.e.f. 31 May 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Alembic Pharma receives USFDA EIR for Karakhadi API facility

The inspection was conducted at the API-III facility from 17th March 2025 to 21st March 2025. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. Shares of Alembic Pharmaceuticals shed 0.78% to Rs 962.70 on the BSE.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Alembic Pharmaceuticals AGM scheduled

Alembic Pharmaceuticals announced that the 15th Annual General Meeting(AGM) of the company will be held on 5 August 2025.Powered by Capital Market - Live

4 weeks agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Alembic Pharmaceuticals Ltd (APLLTD) today?

    The share price of APLLTD as on 10th July 2025 is ₹977.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Alembic Pharmaceuticals Ltd (APLLTD) share?

    The past returns of Alembic Pharmaceuticals Ltd (APLLTD) share are
    • Past 1 week: -1.07%
    • Past 1 month: -0.49%
    • Past 3 months: 16.28%
    • Past 6 months: -3.26%
    • Past 1 year: -0.80%
    • Past 3 years: 33.31%
    • Past 5 years: 3.79%

  3. What are the peers or stocks similar to Alembic Pharmaceuticals Ltd (APLLTD)?
  4. What is the dividend yield % of Alembic Pharmaceuticals Ltd (APLLTD) share?

    The current dividend yield of Alembic Pharmaceuticals Ltd (APLLTD) is 1.13.

  5. What is the market cap of Alembic Pharmaceuticals Ltd (APLLTD) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alembic Pharmaceuticals Ltd (APLLTD) is ₹19206.18 Cr as of 10th July 2025.

  6. What is the 52 week high and low of Alembic Pharmaceuticals Ltd (APLLTD) share?

    The 52-week high of Alembic Pharmaceuticals Ltd (APLLTD) is ₹1303.90 and the 52-week low is ₹725.20.

  7. What is the PE and PB ratio of Alembic Pharmaceuticals Ltd (APLLTD) stock?

    The P/E (price-to-earnings) ratio of Alembic Pharmaceuticals Ltd (APLLTD) is 32.92. The P/B (price-to-book) ratio is 3.70.

  8. Which sector does Alembic Pharmaceuticals Ltd (APLLTD) belong to?

    Alembic Pharmaceuticals Ltd (APLLTD) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Alembic Pharmaceuticals Ltd (APLLTD) shares?

    You can directly buy Alembic Pharmaceuticals Ltd (APLLTD) shares on Tickertape. Simply sign up, connect your demat account and place your order.